Pangea Bio
2 known investors
Pangea Bio is a clinical-stage biotech company developing therapies that activate the TrkB receptor pathway to promote neuronal survival and synaptic plasticity. Its lead candidate OT-003 and follow-on OT-1xx series target central nervous system disorders such as neurological and neuropsychiatric diseases.